Boehringer Ingelheim and Zealand Pharma's Nash candidate fast tracked by FDA
Biotech group Zealand Pharma and German partner Boehringer Ingelheim have been given fast track designation by the US FDA for drug candidate BI 456906 meant to treat nonalcoholic steatohepatitis (Nash), Zealand Pharma reveals Wednesday.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL FRANK CHRISTENSEN
Danish biotechnology firm Zealand Pharma and its German partner, Boehringer Ingelheim, can look forward to expedited case processing time of their drug candidate BI 456906 from the US Food and Drug Administration (FDA) now that the treatment has received fast-track status, informs Zealand Pharma in a statement Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
